DRG Market Assessment reports

Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…

Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder marked by increased platelet destruction and impaired megakaryocyte production. Bleeding ranges from petechiae to lifethreatening…

Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor (TNF)-alpha inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb’s…

Treatment of CSU and CIndU is dominated by oral medications, including approved therapies such as first- and second-generation antihistamines and a range of off-label options (e.g.,…

The treatment landscape for advanced platinumresistant ovarian cancer remains highly challenging, as conventional singleagent chemotherapies provide limited and shortlived benefit. Unlike the…

Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…

Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…

The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…

First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…

Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…

Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…